Skip to main content

Table 1 Summary of studies monitoring RAS mutations in ctDNA of mCRC patients receiving anti-EGFR therapies

From: Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

Reference Methods for ctDNA measurement Patients (n) Previous chemotherapy exposure Anti-EGFR therapy Rate of detected circulating RAS mutations during treatment (%) Potential clinical value
Diaz LA et al. [13] BEAMing 28 yes panitumumab 38 Circulating KRAS mutations generally occurred 5 to 6 months after anti-EGFR therapy.
Misale S et al. [14] Pyrosequencing or BEAMing 10 yes cetuximab or panitumumab 60 Circulating KRAS mutations were frequently detected in acquired resistance to anti-EGFR therapies.
Toledo RA et al. [30] BEAMing 23 no cetuximab 13 Abrupt increase in mutant cfDNA correlated with eminent clinical deterioration.
Vidal J et al. [31] BEAMing 18 unknown cetuximab or panitumumab 39 Circulating RAS mutations correlated with acquired resistance to anti-EGFR therapies.